Munich-based healthtech startup Meliodays Medical is raising 800,000 euros in a pre-seed financing round. The round was significantly oversubscribed and was led by Capacura with participation from FS Life Science Investment and other early-stage investors and business angels specializing in the healthcare market. Simone Sabbione, co-founder and CEO of Meliodays Medical, expressed her delight:
“We are delighted to have won such experienced healthcare and impact investors for our first funding round and warmly welcome them as shareholders of Meliodays. Their investment and the great interest in our significantly oversubscribed pre-seed round show that menstrual pain is now recognized as a serious health burden for large parts of the global population. Now we can finally work on urgently needed solutions.”
Alternative to common treatment methods
With this financing round, Meliodays Medical wants to advance the development of MelioOne, an innovative hormone-free, locally acting therapy for treating menstrual pain. The therapy is intended to offer an innovative alternative to common treatment options such as hormone therapy and painkillers, which are often associated with unwanted systemic side effects.
The fresh capital will be used specifically to complete the preclinical testing of MelioOne’s innovative intrauterine application. The treatment uses proven polymer technology to release a small amount of painkillers directly in the uterus. This enables targeted relief of menstrual pain without systemic side effects occurring. In the long term, the technology could also be used to treat endometriosis, another condition associated with painful symptoms.
Patented in over 150 countries
The Munich-based startup has already secured patent rights for MelioOne in over 150 countries worldwide. With this broad international protection, the company plans to scale its innovative technology globally and offer menstruating people a new, effective and low-risk treatment option.
